Connect with us

Health

Germany Approves Limited Use of Psilocybin Therapy for Depression in Landmark Move

Published

on

In a major breakthrough for mental health treatment in Europe, Germany’s medicine regulator has approved the use of psilocybin therapy for select patients suffering from treatment-resistant depression. The move marks the first time within the European Union that psilocybin—the psychoactive compound found in so-called “magic mushrooms”—will be made available under a compassionate use programme.

The decision, announced by the Federal Institute for Drugs and Medical Devices (BfArM), allows for the controlled use of psilocybin in “justified exceptional cases.” Only patients who have not responded to standard treatments for depression will be eligible, and therapy must be conducted under strict medical supervision.

Dr. Gerhard Gründer, head of the molecular neuroimaging department at the Central Institute of Mental Health (CIMH) in Mannheim, which submitted the request for the programme, described the development as a “milestone.” He noted that for patients facing severe depression with no effective alternatives, psilocybin therapy could be “a medically and ethically justifiable option.”

According to CIMH, between 20% and 30% of people diagnosed with depression do not respond adequately to existing medications or therapies. Recent research suggests that psilocybin may help by disrupting ingrained thought patterns and enhancing brain connectivity, offering potential relief where conventional treatments fail.

While optimism around psychedelics is growing, some researchers caution that results from early clinical trials have proven difficult to replicate. Nonetheless, momentum continues to build across Europe. Earlier this month, the Czech Republic also legalised psilocybin for medical use in specific mental health conditions.

Germany’s decision follows a broader wave of interest in psychedelic-assisted therapies for mental health issues, including anxiety, post-traumatic stress disorder (PTSD), and addiction. Clinical trials across Europe are currently exploring the efficacy of psychedelics, including a major EU-funded study investigating psilocybin’s role in treating anxiety and depression in patients with progressive neurological diseases such as multiple sclerosis (MS) and ALS.

See also  Study Links Navigational Tasks in Driving Professions to Lower Alzheimer’s Death Rates

Approval for widespread clinical use of psilocybin in Germany is not expected for several years. However, advocates say the compassionate use model is a critical interim step. The Psychedelic Access And Research European Alliance (PAREA), a nonprofit group promoting responsible access to these treatments, said such programmes can offer real-world insights and support patients who “cannot wait” for formal approval.

Dr. Gründer said CIMH anticipates high demand for the programme, noting that “experience from Switzerland shows that demand far exceeds the available supply.”

“We must therefore continue to work on bringing psychedelics such as psilocybin into standard care for the treatment of mental illness,” he added.

Health

Study Finds AI Systems Can Repeat Fake Medical Claims When Framed Credibly

Published

on

“Large language models accept fake medical claims if presented as realistic in medical notes and social media discussions, a study has found.”

As more people turn to the internet to research symptoms, compare treatments and share personal health experiences, artificial intelligence tools are increasingly being used to answer medical questions. A new study warns that many of these systems remain vulnerable to medical misinformation, particularly when false claims are presented in authoritative or realistic language.

The findings, published in The Lancet Digital Health, show that leading artificial intelligence systems can mistakenly repeat incorrect medical information when it appears in formats that resemble professional healthcare documents or trusted online discussions. Researchers analysed how large language models respond when faced with false medical statements written in a credible tone.

The study examined responses from 20 widely used language models, including systems developed by OpenAI, Meta, Google, Microsoft, Alibaba and Mistral AI, as well as several models specifically fine-tuned for medical use. In total, researchers assessed more than one million prompts designed to test whether AI would accept or reject fabricated health information.

Fake statements were inserted into real hospital discharge notes, drawn from common health myths shared on Reddit, or embedded in simulated clinical scenarios written to resemble authentic healthcare guidance. Across all models tested, incorrect information was accepted around 32 percent of the time. Performance varied significantly, with smaller or less advanced models accepting false claims in more than 60 percent of cases, while more advanced systems, including ChatGPT-4o, did so in roughly 10 percent of responses.

See also  NHS Warns of Rising Risks as Cosmetic Leg-Lengthening Surgeries Gain Popularity

The researchers also found that medical fine-tuned models performed worse than general-purpose systems, raising concerns about tools designed specifically for healthcare use.

“Our findings show that current AI systems can treat confident medical language as true by default, even when it’s clearly wrong,” said Eyal Klang of the Icahn School of Medicine at Mount Sinai, one of the study’s senior authors. He added that how a claim is written often matters more to the model than whether it is accurate.

Some of the accepted misinformation could pose real risks to patients. Several models endorsed claims such as Tylenol causing autism during pregnancy, rectal garlic boosting immunity, mammograms causing cancer, and tomatoes thinning blood as effectively as prescription medication. In another case, a discharge note incorrectly advised patients with oesophageal bleeding to drink cold milk, which some models repeated without flagging safety concerns.

The study also tested how AI systems responded to flawed arguments known as fallacies. While many fallacies prompted scepticism, models were more likely to accept false claims framed as expert opinions or warnings of catastrophic outcomes.

Researchers say future work should focus on measuring how often AI systems pass on falsehoods before they are used in clinical settings. Mahmud Omar, the study’s first author, said the dataset could help developers and hospitals stress-test AI tools and track improvements over time.

The authors said stronger safeguards will be essential as AI becomes more deeply embedded in healthcare decision-making.

Continue Reading

Health

Moderate Caffeine Intake Linked to Lower Dementia Risk, Study Finds

Published

on

“Moderate daily consumption of caffeine is associated with a lower risk of dementia and slower cognitive decline, according to a new study.”

Drinking coffee or tea on a regular basis may help support healthy brain ageing, researchers reported, adding to growing evidence that lifestyle and dietary factors can influence cognitive health later in life. The findings suggest that moderate caffeine intake could play a modest role in reducing the risk of dementia and preserving cognitive function over time.

The study, published in JAMA, found that consuming two to three cups of caffeinated coffee or one to two cups of tea per day was associated with up to an 18% lower risk of developing dementia. The strongest benefits were seen among participants with moderate caffeine intake, though higher levels of consumption did not appear to cause harm and showed similar protective effects.

“When searching for possible dementia prevention tools, we thought something as prevalent as coffee may be a promising dietary intervention,” said senior author Daniel Wang, an associate scientist at the Mass General Brigham Department of Medicine and an assistant professor at Harvard Medical School.

Researchers analysed data from more than 130,000 participants who underwent repeated dietary, cognitive and dementia assessments. The participants were followed for as long as 43 years, allowing the team to assess long-term patterns of coffee and tea consumption and their potential impact on cognitive health. During the follow-up period, 11,033 participants developed dementia.

The analysis showed that both men and women with the highest caffeine intake had an 18% lower risk of dementia compared with those who consumed little or no caffeine. Coffee drinkers also reported fewer symptoms of subjective cognitive decline, defined as self-perceived memory loss or confusion, with rates of 7.8% compared with 9.5% among those who drank less coffee.

See also  Counterfeit COVID-19 and Influenza Test Kits Reach European Market

Scientists believe that coffee and tea may offer neuroprotective benefits due to bioactive compounds such as caffeine and polyphenols. These substances are thought to reduce inflammation and cellular damage, while supporting blood vessel health in the brain. Previous studies have also linked caffeine consumption to improved insulin sensitivity and better vascular function, both of which are associated with cognitive health.

The authors cautioned that the research was observational and cannot prove a direct cause-and-effect relationship. The study also did not differentiate between types of coffee or tea, or account for variations in preparation methods, including roast levels, origins or brewing techniques.

The researchers noted that early prevention remains crucial, as current dementia treatments provide limited benefit once symptoms develop. Dementia typically progresses from subjective cognitive decline to mild cognitive impairment before advancing to clinical dementia.

While the findings are encouraging, the authors stressed that caffeine consumption is only one of several factors that may help protect cognitive function with age. “Our study suggests that caffeinated coffee or tea consumption can be one piece of that puzzle,” Wang said.

Continue Reading

Health

Growing Research Links Tattoos to Possible Cancer Risks, Experts Say

Published

on

Tattoos are more popular than ever, but a growing body of research suggests a connection between permanent ink and certain types of cancer. How concerned should the public be?

From tribal sleeves to lower-back butterflies, humans have been inking their skin for thousands of years. For most, the main concern has been the fear of future regrets. However, recent studies suggest that tattoos could carry more serious long-term health risks.

The popularity of tattoos has risen sharply in recent years. Research published in the European Journal of Public Health estimates that between 13 and 21 percent of people in Western Europe now have at least one tattoo. Despite this prevalence, relatively little is known about the potential long-term effects of permanent ink.

Previous studies have shown that tattoo pigments can accumulate in the lymph nodes, sometimes causing inflammation and, in rare cases, lymphoma—a type of blood cancer. A 2025 study by the University of Southern Denmark (SDU) expanded on this, reporting that individuals with tattoos may face higher risks of skin cancer and lymphoma. Using a cohort of randomly selected twins, the researchers found that tattooed participants had nearly four times the risk of skin cancer compared with their non-tattooed siblings.

The study also suggested that tattoo size could affect risk, with designs larger than the palm associated with higher hazard rates.

“We have evidence that there is an association [between the amount of ink and risk] for lymphoma and for skin cancer,” said Signe Bedsted Clemmensen, co-author of the study and assistant professor of biostatistics at SDU. “For lymphoma, the hazard rate is 2.7 times higher, so this is quite a lot. And for skin cancers, before it was 1.6 and now it’s 2.4. This indicates that the more ink you have, the higher the risk, the higher the hazard rate.”

See also  Chinese Nationals Charged in U.S. with Smuggling Toxic Fungus Labeled a Potential Agroterrorism Threat

Clemmensen emphasized that these findings remain preliminary, with many variables—including ink types, tattoo placement, and genetic and environmental factors—still under investigation. “The bottom line is, more research is needed,” she said. “But also, the next step I think is studying the biological mechanisms [of getting tattooed] and trying to understand what happens there.”

Experts also note other risks unrelated to cancer. Tattoo inks consist of pigments combined with a carrier fluid to deposit color into the dermis. Some inks, often imported, can contain trace amounts of heavy metals such as nickel, chromium, cobalt, and lead, which can trigger allergic reactions or immune sensitivity. In 2022, the European Union restricted more than 4,000 hazardous substances in tattoo inks under its REACH regulations.

While tattoos are generally considered safe when applied hygienically, the long-term health consequences remain uncertain. “It’s up to each of us how we choose to live our lives, right? But as a researcher, it’s also my job to inform people of these risks,” Clemmensen said. “Or, when it comes to tattooing, right now it’s more about informing people about how little we know.”

Continue Reading

Trending